| Cat. # | Size | Qty. | Price |
|---|---|---|---|
| 39433T | 1 Kit (6 x 20 microliters) |
|
| Product Includes | Quantity | Applications | Reactivity | MW(kDa) | Isotype |
|---|---|---|---|---|---|
| MyD88 (D80F5) Rabbit mAb 4283 | 20 µl |
|
H M R Hm Mk | 33 | Rabbit IgG |
| IRAK1 (D51G7) Rabbit mAb 4504 | 20 µl |
|
H M Mk | 78-105 | Rabbit IgG |
| IRAK2 Antibody 4367 | 20 µl |
|
H M R Mk | 62 | Rabbit |
| IRAK4 Antibody 4363 | 20 µl |
|
H M R Mk | 55 | Rabbit |
| Phospho-IRAK4 (Thr345/Ser346) (D6D7) Rabbit mAb 11927 | 20 µl |
|
H | 55 | Rabbit IgG |
| TRAF6 (E2K9D) Rabbit mAb 67591 | 20 µl |
|
H M R | 60 | Rabbit IgG |
| TBK1/NAK (E8I3G) Rabbit mAb 38066 | 20 µl |
|
H M R | 84 | Rabbit IgG |
| Phospho-TBK1/NAK (Ser172) (D52C2) XP® Rabbit mAb 5483 | 20 µl |
|
H M | 84 | Rabbit IgG |
| Anti-rabbit IgG, HRP-linked Antibody 7074 | 100 µl |
|
Goat |
Product Information
Monoclonal antibodies are produced by immunizing animals with recombinant protein specific to a central region of mouse TRAF6 proteins, with synthetic phosphopeptides corresponding to residues surrounding Thr345/Ser346 and Ser172 of human IRAK4 and TBK1/NAK1 proteins, respectively, and with synthetic peptides corresponding to residues surrounding Cys233 of human MyD88 protein and residues near the carboxyl termini of mouse IRAK1 and human TBK1/NAK protein. Polyclonal antibodies are produced by immunizing animals with synthetic peptides corresponding to residues at the carboxy terminus of mouse IRAK2 and residues surrounding Lys41 of human IRAK4. Antibodies were purified by protein A and peptide affinity chromatography.
Toll-like receptors (TLRs) are a large family of so-called pattern recognition receptors (PRRs) that detect pathogen associated molecular patterns (PAMPs) and danger associated molecular patterns (DAMPs) (1,2). Upon activation, TLRs initiate two main signaling pathways through their C-terminal cytoplasmic Toll/Il-1 receptor (TIR) domain that couples with TIR domain-containing adaptors MyD88 and TRIF. The MyD88-dependent pathway is initiated by the formation of a large oligomeric protein complex termed myddosome. Myddosome is one of so-called supramolecular organizing centers (SMOCs), a signaling organelle that is common for PRRs in the innate immune system. Myddosome formation promotes IRAK4 activation, which in turn activates IRAK1 and later, IRAK2. TRAF6 is then recruited and activated through the binding sites within IRAKs. Activated TRAF6 is released to the cytosol and triggers the IKK complex to activate the NF-κB pathway to mediate the expression of pro-inflammatory cytokines and chemokines (3-7). Recently, it was also found that TBK1 is recruited to the myddosome complex and activated to induce aerobic glycolysis (8).
Explore pathways related to this product.
STRING - Known and Predicted Protein-Protein Interactions.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
PhosphoSitePlus®